Home > News > Headline News > Archive

Click on title to read the full article.

Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2

November 26, 2013

By Onc Live

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups. The data were presented at the 2013 Breast Cancer Symposium.

Novartis chases Pfizer in hot new breast cancer drug area

November 22, 2013

By Reuters

The significance of the new targeted approach to fighting cancer was highlighted in April when U.S. regulators granted a "breakthrough therapy" designation to palbociclib, based on impressive results seen in mid-stage trials.

Penn Study Identifies New Trigger for Breast Cancer Metastasis

November 6, 2013

Researchers have revealed how a reduction in mitochondrial DNA content leads human breast cancer cells to take on aggressive, metastatic properties.

Managing mTOR Inhibitor Side Effects in Breast Cancer

November 5, 2013

By OncLive

Last year the FDA approved everolimus for the treatment of HR-positive, HER2-negative breast cancer, when given in combination with the aromatase inhibitor (AI) exemestane, in previously treated postmenopausal women, based on findings of the BOLERO-2 trial.

Pfizer Pharmaceutical launches global breast cancer clinical trial at Southern Cancer Center

November 4, 2013

Specifically, the study will evaluate palbociclib in combination with fulvestrant in women with hormone positive, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy.